Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001209191-23-012015

Chief Executive Officer sold 32,861 shares at $4.66 ($153,132)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Ballal Rahul D. Chief Executive Officer 2023-02-22 Sale −32,861 $4.66 $153,132 87,835 D: show line 1 in the form
Open-market sales · 32,861 sh · avg $4.66 · $153,132
Loading xslF345X03/doc4.xml…